# Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab

> **NCT04306965** · PHASE2 · COMPLETED · sponsor: **Tufts Medical Center** · enrollment: 10 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Apremilast

## Key facts

- **NCT ID:** NCT04306965
- **Lead sponsor:** Tufts Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-01
- **Primary completion:** 2022-06-23
- **Final completion:** 2022-08-18
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04306965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04306965, "Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04306965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*